News & Updates
Showing Endocrinology articles
Showing
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.
GLP-1RA prevents glaucoma development in T2D patients
Use of glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) appears to have protective benefits against the development of glaucoma compared with exposure to other second-line antihyperglycaemic medications, according to a study.
Canagliflozin lowers HbA1c in children with T2D
Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
Adding sodium–glucose co-transporter-2 (SGLT2) inhibitors to usual care in the treatment of hospitalized patients with COVID-19 does not necessarily lead to improved survival, according to the results of a meta-analysis.
Diabetes, insulin use up risk of death, cardiac events in AF patients
In patients with atrial fibrillation (AF), being diabetic contributes to an increased risk of all-cause death, cardiovascular disease (CVD), myocardial infarction (MI), major bleeding, and major adverse cardiovascular events (MACE), results of the GLORIA-AF study have shown.
